

# TABLE OF CONTENTS

August 11 & 18, 2008

No. 2102

## BUSINESS

- 1 Nippon Chemiphar Expects 34.3% Growth Rate for Generics
  - Multiple Options for Future Relationship with Ranbaxy
  - Sales Up with Sharp Drop in Profits in 1st Qtr
- 3 **Stop Press**
  - Kowa Enters US Market by Acquiring ProEthic Pharm.
- 3 MTPC Licenses Drug for Hyperparathyroidism from Cytochroma of Canada
- 4 Sales of Avastin, Herceptin Disappointing: Chugai
  - Chugai to Participate in Number of Multinational Clinical Trials
  - Roche Will Not Want to Make Chugai Wholly-Owned Subsidiary: Mr Kodama
  - Chugai Outsources Manufacturing of Tocilizumab Drug Substance to Genentech
- 5 Bayer to Increase Sales of Oncology Products to ¥50 Bil.
- 6 GSK's New Business Strategy Puts Emphasis on Japanese Market
- 6 Suzuken to Acquire a Dispensing Pharmacy Chain
- 6 Matsumotokiyoshi Acquires Mogi Pharmaceutical
- 7 Avapro Holds Top Position 2 Months in a Row: Rep Track Survey
- 8 Price Settlement Rate Remains at 18% as of June 30: NPhA
  - Elimination of Wholesalers' Losses Not Progressing
  - Mediceo Paltac Reports Price Settlement Rate of 46.1% as of June 30
- 10 JPMA Members Improving Distribution Business Practices: Mr Negi
- 10 MSNW Supports of Rational Drug Pricing
- 11 Tokushukai Committed to Settling Prices by End of September
- 11 **BUSINESS NEWS IN BRIEF**
  - Eisai Licenses  $\alpha$ -Lipon 300 STADA from Health Vision Enterprise in China
  - Astellas Launches Mycamine in the UK
  - Otsuka HD Controls 4 Wholly-Owned Subsidiaries, Including Otsuka Pharm. and Taiho

## REGULATORY

- 12 GSK's Lamotrigine Recommended for Approval
  - Neoral for Atopic Dermatitis
  - No Rhabdomyolysis Reported in PMS of Lipovas
- 14 Taxotere to Be Approved for Prostate Cancer
- 14 ¥220 Bil. Cut in Social Security Spending Approved by Cabinet
  - Cuts into Social Security Spending Will Be Reduced if New Financial Resources Are Found: Mr Masuzoe
- 15 Gov't Announces Five Plans for Assurance

## REGULATORY NEWS IN BRIEF

- Seikagaku Applies for Gel-200 in US
- Erbitux Approved as First-Line Treatment for mCRC in EU: Merck
- Rivaroxaban Recommended for Approval in the EU: Bayer HealthCare
- FDA Recommends Approval of Actemra for RA: Chugai, Roche
- Eisai Receives Not-Approvable Letter from US FDA for Fospropofol

## R&D

- 16 Takeda Develops Candesartan + Amlodipine Combination in Japan
- 16 Amgen Shows Inhibition of Fractures by Denosumab
- 17 siRNA Therapeutic to Enter PI in 2009: GeneCare
- 17 9 Asian Studies Started in 2007
  - South Korea, Taiwan Selected in Most Asian Studies
- 18 More Research Centers in China
- 19 Gov't Plans to Create 20 "Super Tokku"
  - Research Funds and Regulatory Support Provided at the Same Time
  - *Koroshō* Wants to See 1/3 of World's New Regenerative Medical Technologies Developed in Japan
- 20 **R&D NEWS IN BRIEF**
  - Iressa's Superiority Demonstrated in Asians: AZ

## GENERIC

- 20 JRCS Considers Joint Purchase of Generics
- 20 **GENERIC NEWS IN BRIEF**
  - Increases in Use of Generics Prerequisite for NHI Pricing System Reform: Mr Isobe

## MEDICAL FACILITIES & NURSING CARE

- 21 Isentress Key Drug in HIV Treatment: Banyu
  - Drug Resistant HIV Increasing
- 21 Long-term Lipovas Administration Useful: Banyu
- 21 Vaccines Effective in Preventing Bacterial Meningitis: Wyeth
- 22 Survival Improved by Treatment of Post-stroke Depression
- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
  - 10 Patients' Organizations Inaugurate Council
  - Subarachnoid Hemorrhage Not Diagnosed in 5-8% of Patients
  - Over 70% of Municipality Hospitals Still Deficit-Ridden: Survey

## MEDICAL DEVICE

- 23 **MEDICAL DEVICE NEWS IN BRIEF**
  - FALCO Biosystems Start Gene Testing for Familial Breast, Ovarian Cancers